|Ms. Katherine A. Anderson CPA||CFO, Chief Accounting Officer & Sec.||344.87k||N/A||59|
|Dr. Larry M. Dillaha M.D.||Chief Exec. Officer, Pres and Director||N/A||N/A||53|
|Dr. Joachim F. Wernicke M.D., Ph.D.||Chief Medical Officer||N/A||N/A||69|
Repros Therapeutics Inc., a biopharmaceutical company, focuses on the development of various drugs to treat hormonal and reproductive system disorders for male and female in the United States. Its product portfolio include Proellex that is in Phase III clinical trials for the treatment of symptoms associated with uterine fibroids, as well as in Phase II clinical trial for the treatment of endometriosis; and enclomiphene, a single isomer of clomiphene citrate, which is in Phase III clinical trials for the treatment of secondary hypogonadism in overweight men wishing to restore normal testicular function. The company was founded in 1987 and is based in The Woodlands, Texas.
Repros Therapeutics Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.